RT Journal Article
SR Electronic
T1 Racial and workplace disparities in seroprevalence of SARS-CoV-2 in Baton Rouge, Louisiana, July 15-31, 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.26.20180968
DO 10.1101/2020.08.26.20180968
A1 Feehan, Amy K.
A1 Velasco, Cruz
A1 Fort, Daniel
A1 Burton, Jeffrey H.
A1 Price-Haywood, Eboni
A1 Katzmarzyk, Peter T.
A1 Garcia-Diaz, Julia
A1 Seoane, Leonardo
YR 2020
UL http://medrxiv.org/content/early/2020/09/01/2020.08.26.20180968.abstract
AB Using paired molecular and antibody testing for SARS-CoV-2 infection, we determined point prevalence and seroprevalence in a municipality in Louisiana, USA during the second phase of reopening. Infections were highly variable by race, work environment, and ZIP code. Census-weighted seroprevalence and point prevalence were 3.6% and 3.0%, respectively.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the Baton Rouge Area Foundation, Louisiana COVID-19 Health Equity Task Force and The Humana Foundation, with additional support from The Blue Cross and Blue Shield of Louisiana Foundation, and Healthy Blue. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ochsner Health IRB approved this study and can be contacted at irb{at}ochsner.org or by phone at 504-842-3535.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data is available upon reasonable request to the corresponding author.